MedTrace Logo

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

NCT04636008 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-08-06

No results posted yet for this study

Summary

This prospective, single-arm study is conducted to investigate the safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite instability-high (MSI-H)/ DNA mismatch repair-deficient (dMMR) non-metastatic rectal cancer.

Conditions

  • Anti-PD-1 Antibody
  • Radiotherapy
  • Rectal Cancer
  • MSI-H
  • Mmr Deficiency

Interventions

DRUG

Sintilimab

Sintilimab+Hypofractionated radiotherapy

RADIATION

Hypofractionated Radiotherapy

Hypofractionated Radiotherapy

Sponsors & Collaborators

  • First Affiliated Hospital of Chongqing Medical University

    collaborator OTHER

  • Yunnan Cancer Hospital

    collaborator OTHER

  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER

  • Chengdu Third People's Hospital

    collaborator UNKNOWN

  • The Affiliated Hospital Of Southwest Medical University

    collaborator OTHER

  • West China Hospital

    lead OTHER

Principal Investigators

  • Meng Qiu, M.D. · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-14
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04636008 on ClinicalTrials.gov